Emerald Advisers LLC Invests $22.64 Million in Guardant Health, Inc. (NASDAQ:GH)

Emerald Advisers LLC acquired a new stake in Guardant Health, Inc. (NASDAQ:GH - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 531,424 shares of the company's stock, valued at approximately $22,639,000. Emerald Advisers LLC owned approximately 0.43% of Guardant Health at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of GH. New York State Common Retirement Fund boosted its stake in shares of Guardant Health by 184.1% during the first quarter. New York State Common Retirement Fund now owns 106,884 shares of the company's stock worth $4,553,000 after buying an additional 69,257 shares during the period. Emerald Mutual Fund Advisers Trust purchased a new position in Guardant Health in the first quarter valued at about $13,942,000. Xponance Inc. increased its holdings in Guardant Health by 6.8% in the first quarter. Xponance Inc. now owns 9,116 shares of the company's stock valued at $388,000 after buying an additional 582 shares in the last quarter. Cerity Partners LLC increased its holdings in Guardant Health by 6.4% in the first quarter. Cerity Partners LLC now owns 145,475 shares of the company's stock valued at $6,197,000 after buying an additional 8,725 shares in the last quarter. Finally, Values First Advisors Inc. increased its holdings in Guardant Health by 5.5% in the first quarter. Values First Advisors Inc. now owns 29,597 shares of the company's stock valued at $1,263,000 after buying an additional 1,538 shares in the last quarter. Institutional investors and hedge funds own 92.60% of the company's stock.

Analyst Ratings Changes

GH has been the subject of a number of recent research reports. Scotiabank reissued an "outperform" rating on shares of Guardant Health in a research note on Monday, May 5th. Evercore ISI raised shares of Guardant Health to a "strong-buy" rating in a research note on Monday. Barclays raised their price objective on shares of Guardant Health from $55.00 to $60.00 and gave the stock an "overweight" rating in a research note on Thursday, May 1st. Piper Sandler reissued an "overweight" rating and set a $60.00 price objective (up from $50.00) on shares of Guardant Health in a research note on Tuesday, May 6th. Finally, Stifel Nicolaus raised their price objective on shares of Guardant Health from $53.00 to $60.00 and gave the stock a "buy" rating in a research note on Thursday, May 1st. Twenty-one analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $53.76.

Insider Buying and Selling at Guardant Health

In related news, Director Musa Tariq sold 3,213 shares of Guardant Health stock in a transaction on Wednesday, June 18th. The shares were sold at an average price of $49.47, for a total transaction of $158,947.11. Following the transaction, the director owned 7,190 shares in the company, valued at approximately $355,689.30. The trade was a 30.89% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Ian T. Clark sold 6,672 shares of Guardant Health stock in a transaction on Tuesday, June 17th. The shares were sold at an average price of $48.38, for a total transaction of $322,791.36. Following the transaction, the director owned 9,851 shares in the company, valued at $476,591.38. The trade was a 40.38% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 342,274 shares of company stock worth $17,080,589. Corporate insiders own 6.10% of the company's stock.

Guardant Health Stock Performance

NASDAQ GH traded down $0.28 during mid-day trading on Wednesday, reaching $47.81. 1,517,494 shares of the stock were exchanged, compared to its average volume of 2,167,033. The stock has a market capitalization of $5.92 billion, a PE ratio of -14.10 and a beta of 1.44. The business's fifty day simple moving average is $45.94 and its 200 day simple moving average is $44.03. Guardant Health, Inc. has a 1-year low of $20.14 and a 1-year high of $53.42.

Guardant Health (NASDAQ:GH - Get Free Report) last announced its quarterly earnings results on Wednesday, April 30th. The company reported ($0.49) earnings per share for the quarter, beating analysts' consensus estimates of ($0.57) by $0.08. The company had revenue of $203.47 million during the quarter, compared to analyst estimates of $189.91 million. The firm's revenue for the quarter was up 20.8% compared to the same quarter last year. During the same quarter last year, the business earned ($0.46) EPS. On average, analysts anticipate that Guardant Health, Inc. will post -2.9 EPS for the current year.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.